Antibody kinetics between birth and three months of life in healthy infants with natural exposure to Group B streptococcus: A UK cohort study.

Autor: Karampatsas K; Centre for Neonatal and Paediatric Infection, St. George's, University of London, London, United Kingdom. Electronic address: kkarampa@sgul.ac.uk., Hall T; Centre for Neonatal and Paediatric Infection, St. George's, University of London, London, United Kingdom., Voysey M; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom., Carreras-Abad C; Centre for Neonatal and Paediatric Infection, St. George's, University of London, London, United Kingdom., Cochet M; Centre for Neonatal and Paediatric Infection, St. George's, University of London, London, United Kingdom., Ramkhelawon L; Centre for Neonatal and Paediatric Infection, St. George's, University of London, London, United Kingdom., Peregrine E; Department of Obstetrics and Gynaecology, Kingston Hospital NHS Foundation Trust, London, United Kingdom., Andrews N; UK Health Security Agency, London, United Kingdom., Heath PT; Centre for Neonatal and Paediatric Infection, St. George's, University of London, London, United Kingdom., Le Doare K; Centre for Neonatal and Paediatric Infection, St. George's, University of London, London, United Kingdom; Pathogen Immunology Group, UK Health Security Agency, Porton Down, United Kingdom; Makerere University Johns Hopkins University, Kampala, Uganda.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2024 May 10; Vol. 42 (13), pp. 3230-3238. Date of Electronic Publication: 2024 Apr 15.
DOI: 10.1016/j.vaccine.2024.04.014
Abstrakt: Introduction: Capsular polysaccharide (CPS) serotype-specific Immunoglobulin G (IgG) in cord blood has been proposed as a correlate of protection against invasive Group B Streptococcus (iGBS) disease. Although protective levels are required in infants throughout the window of vulnerability up to 3 months of age, little is known regarding the kinetics of GBS-specific IgG over this period.
Methods: We enrolled 33 healthy infants born to mothers colonized with GBS. We collected cord blood and infant blood samples either at one (21-35 days), two (49-63 days), or three months of age (77-91 days). We measured GBS serotype-specific CPS IgG concentrations and calculated the decay rate using a mixed-effects model. We further explored whether the antibody kinetics were affected by common maternal and infant factors and estimated the correlation between IgG concentration at birth and one, two, and three months of age.
Results: The half-life estimate of IgG concentration for homologous and non-homologous GBS serotypes in paired samples with detectable IgG levels at both time points was 27.4 (95 % CI: 23.5-32.9) days. The decay rate did not vary by maternal age (p = 0.7), ethnicity (p = 0.1), gravida (p = 0.1), gestation (p = 0.7), and infant sex (p = 0.1). Predicted IgG titres above the assay lower limit of quantification on day 30 strongly correlated with titres at birth (Spearman correlation coefficient 0.71 [95 % CI: 0.60-0.80]).
Conclusion: Our results provide a basis for future investigations into the use of antibody kinetics in defining a serocorrelate of protection against late-onset iGBS disease.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Paul Heath reports financial support was provided by National Institute for Health Research. MV is a contributor to intellectual property licensed by Oxford University Innovation to AstraZeneca. PTH has conducted studies on behalf of St George’s University of London funded by GBS vaccine manufacturers, including Minervax and Pfizer, but receives no personal funding for these activities. KLD is supported by Future Leaders Fellowships by UK Research and Innovation Future Leaders Fellowship (MR/S016570/1) and has conducted studies on behalf of St George’s University of London funded by GBS vaccine manufacturers, including Minervax and Pfizer, but receives no personal funding for these activities. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.].
(Copyright © 2024 The Authors. Published by Elsevier India Pvt Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: